Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2017

01-09-2017 | Letter to the Editor

Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)

Authors: Marcelo Pitombeira de Lacerda, Nayara Ribeiro Guedes, Patricia Eiko Yamakawa, Andre Domingues Pereira, Ana Rita Brito Medeiros da Fonseca, Maria Lourdes Lopes Ferrari de Chauffaille, Matheus Vescovi Goncalves, Mihoko Yamamoto, Celso Arrais Rodrigues

Published in: Annals of Hematology | Issue 9/2017

Login to get access

Excerpt

Dear editor, …
Literature
1.
Rogers KA, Woyachn JA (2016) Secondary autoimmune cytopenias in chronic lymphocytic leukemia. Semin Oncol 43:300–310CrossRefPubMed
2.
Tsang M, Parikh SA (2017) A concise review of autoimmune cytopenias in chronic lymphocytic leukemia. Curr Hematol Malig rep 12(1):29–38CrossRefPubMed
3.
Seymour JF, Ma S, Brander DM et al (2017) Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 18(2):230–240CrossRefPubMedPubMedCentral
4.
Mato AR, Hill BT, Lamanna N et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol 2017 mdx031.
5.
Montillo M, O'Brien S, Tedeschi A et al (2017) Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J 7(2):e524CrossRefPubMedPubMedCentral
Metadata
Title
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)
Authors
Marcelo Pitombeira de Lacerda
Nayara Ribeiro Guedes
Patricia Eiko Yamakawa
Andre Domingues Pereira
Ana Rita Brito Medeiros da Fonseca
Maria Lourdes Lopes Ferrari de Chauffaille
Matheus Vescovi Goncalves
Mihoko Yamamoto
Celso Arrais Rodrigues
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3039-1

Other articles of this Issue 9/2017

Annals of Hematology 9/2017 Go to the issue

Original Article

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase

Letter to the Editor

Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice

Letter to the Editor

Pregnancy in patients with thrombocytopenia and absent radii (TAR) syndrome

Letter to the Editor

In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study

Original Article

Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia

Original Article

Transcranial color Doppler in stroke-free adult patients with sickle cell disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits